INVENTIVA (EPA:IVA) Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D
Directive transparence : information réglementée
Inventiva and Sino Biopharm announce licensing and collaboration agreement...
Inventiva announces the schedule of publication and presentation of its...
Inventiva Reports 2022 First-Half Financial Information¹
Inventiva announces the screening of the first patient in LEGEND, a Phase...
Inventiva to host a webcast with Key Opinion Leaders following the EASL...
Inventiva announces three scientific presentations at the EASL...
Inventiva joins the Euronext Tech Leaders segment
Inventiva announces the presentation of a scientific abstract at the 82nd...
Inventiva announces participation at several investors conferences in May...
Results of the votes of the Combined Shareholders’ Meeting of May 19,...
Voir tous les communiqués de INVENTIVA
©Dissemination technology Webdisclosure.com - copyright 2022 SYMEX ECONOMICS all rights reserved